Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AFM28 |
Synonyms | |
Therapy Description |
AFM28 is a bispecific innate cell engager that redirects CD16A-positive NK cells towards CD123-positive tumor cells, potentially leading to antibody-dependent cellular cytotoxicity and decreased tumor growth (Blood (2022) 140 (Supplement 1): 8815-8816). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AFM28 | AFM-28|AFM 28 | AFM28 is a bispecific innate cell engager that redirects CD16A-positive NK cells towards CD123-positive tumor cells, potentially leading to antibody-dependent cellular cytotoxicity and decreased tumor growth (Blood (2022) 140 (Supplement 1): 8815-8816). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05817058 | Phase I | AFM28 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | FRA | ESP | DNK | 0 |